Key statistics
On Monday, ELEVAI Labs Inc (ELAB:NAQ) closed at 0.0157, 2.61% above its 52-week low of 0.0153, set on Nov 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0173 |
---|---|
High | 0.0173 |
Low | 0.0153 |
Bid | 0.0144 |
Offer | 0.0145 |
Previous close | 0.0201 |
Average volume | 457.94m |
---|---|
Shares outstanding | 614.57m |
Free float | 571.17m |
P/E (TTM) | -- |
Market cap | 12.35m USD |
EPS (TTM) | -0.2924 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
More ▼
- Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
- Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
- CORRECTION - Elevai Labs Inc.
- Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
- Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
- Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
- REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
More ▼